Press Releases

INOVIO’s COVID-19 Vaccine Candidate, INO-4800, Provides Broad Cross-reactive Immune Responses In Humans Against Variants of Concern

Posted on April 15, 2021

INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel

Posted on March 15, 2021

INOVIO to Present at Upcoming Investor Conferences in March

Posted on March 4, 2021

INOVIO Reports Fourth Quarter 2020 and Year-End Financial Results

Posted on March 1, 2021

INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18

Posted on March 1, 2021

INOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO’s VGX-3100 for advanced cervical dysplasia

Posted on February 24, 2021

INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa

Posted on February 23, 2021

INOVIO to Report Fourth Quarter and Full Year 2020 Financial Results on March 1, 2021

Posted on February 16, 2021

INOVIO Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Posted on January 25, 2021

INOVIO Announces Pricing of Public Offering of Common Stock

Posted on January 20, 2021

© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.